PL1809293T3 - Formulacja w postaci aerozolu do inhalacji 5 beta – agonistów - Google Patents

Formulacja w postaci aerozolu do inhalacji 5 beta – agonistów

Info

Publication number
PL1809293T3
PL1809293T3 PL05747843.0T PL05747843T PL1809293T3 PL 1809293 T3 PL1809293 T3 PL 1809293T3 PL 05747843 T PL05747843 T PL 05747843T PL 1809293 T3 PL1809293 T3 PL 1809293T3
Authority
PL
Poland
Prior art keywords
inhalation
aerosol formulation
beta agonists
agonists
beta
Prior art date
Application number
PL05747843.0T
Other languages
English (en)
Inventor
Michael Aven
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34979667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1809293(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of PL1809293T3 publication Critical patent/PL1809293T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04Amoebicides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PL05747843.0T 2004-05-14 2005-05-10 Formulacja w postaci aerozolu do inhalacji 5 beta – agonistów PL1809293T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004024452A DE102004024452A1 (de) 2004-05-14 2004-05-14 Aerosolformulierung für die Inhalation von Betaagonisten

Publications (1)

Publication Number Publication Date
PL1809293T3 true PL1809293T3 (pl) 2016-09-30

Family

ID=34979667

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05747843.0T PL1809293T3 (pl) 2004-05-14 2005-05-10 Formulacja w postaci aerozolu do inhalacji 5 beta – agonistów

Country Status (26)

Country Link
EP (1) EP1809293B1 (pl)
JP (1) JP4620730B2 (pl)
KR (1) KR101288791B1 (pl)
CN (1) CN101056640A (pl)
AR (1) AR049096A1 (pl)
AU (1) AU2005244414B2 (pl)
BR (1) BRPI0511135B8 (pl)
CA (1) CA2564379C (pl)
DE (1) DE102004024452A1 (pl)
DK (1) DK1809293T3 (pl)
EA (1) EA012583B1 (pl)
EC (1) ECSP067004A (pl)
ES (1) ES2575925T3 (pl)
HU (1) HUE027780T2 (pl)
IL (1) IL179218A (pl)
MX (1) MXPA06013216A (pl)
MY (1) MY148403A (pl)
NO (1) NO20065030L (pl)
PE (1) PE20060311A1 (pl)
PL (1) PL1809293T3 (pl)
SG (1) SG152265A1 (pl)
TW (1) TWI356703B (pl)
UA (1) UA87312C2 (pl)
UY (1) UY28891A1 (pl)
WO (1) WO2005110421A2 (pl)
ZA (1) ZA200607462B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
WO2007020227A1 (de) 2005-08-15 2007-02-22 Boehringer Ingelheim International Gmbh Verfahren zur herstellung von betamimetika
JP2009514933A (ja) * 2005-11-09 2009-04-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 吸入用エアロゾル製剤
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
CA2738616A1 (en) * 2008-11-21 2010-05-27 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta agonists
US20110281858A1 (en) * 2008-11-21 2011-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta agonists
JP2015533131A (ja) 2012-10-09 2015-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 咳を治療するためのベータ2−アドレナリン受容体作動薬
WO2018108669A1 (en) 2016-12-12 2018-06-21 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol
BR112022010802A2 (pt) * 2019-12-05 2022-08-23 Syngenta Crop Protection Ag Processo de um passo para a preparação de derivados de feniletilamina

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) * 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
JPH0637388B2 (ja) * 1986-02-17 1994-05-18 千寿製薬株式会社 水性液剤
GB9405019D0 (en) * 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
DE10253282A1 (de) * 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
DE102004019539A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
PT1781298E (pt) * 2004-04-22 2012-02-03 Boehringer Ingelheim Int Combinações farmacêuticas contendo benzoxazinas para o tratamento de doenças respiratórias
DE102004024454A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004024451A1 (de) * 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten

Also Published As

Publication number Publication date
DE102004024452A1 (de) 2005-12-08
JP4620730B2 (ja) 2011-01-26
CN101056640A (zh) 2007-10-17
UA87312C2 (ru) 2009-07-10
ES2575925T3 (es) 2016-07-04
IL179218A0 (en) 2007-03-08
IL179218A (en) 2012-10-31
ZA200607462B (en) 2008-06-25
KR20070022084A (ko) 2007-02-23
CA2564379C (en) 2013-07-30
CA2564379A1 (en) 2005-11-24
HUE027780T2 (en) 2016-11-28
SG152265A1 (en) 2009-05-29
BRPI0511135B8 (pt) 2021-05-25
EA012583B1 (ru) 2009-10-30
MXPA06013216A (es) 2007-02-08
EP1809293B1 (de) 2016-03-16
DK1809293T3 (en) 2016-06-20
WO2005110421A2 (de) 2005-11-24
PE20060311A1 (es) 2006-05-08
BRPI0511135B1 (pt) 2019-11-12
KR101288791B1 (ko) 2013-07-29
EP1809293A2 (de) 2007-07-25
ECSP067004A (es) 2007-02-28
UY28891A1 (es) 2005-12-30
AU2005244414B2 (en) 2010-12-09
BRPI0511135A (pt) 2007-11-27
WO2005110421A3 (de) 2006-03-16
AU2005244414A1 (en) 2005-11-24
TW200608981A (en) 2006-03-16
JP2007537188A (ja) 2007-12-20
MY148403A (en) 2013-04-30
AR049096A1 (es) 2006-06-28
TWI356703B (en) 2012-01-21
NO20065030L (no) 2006-11-30
EA200602017A1 (ru) 2007-06-29

Similar Documents

Publication Publication Date Title
IL190682A0 (en) Aerosol formulation for the inhalation of beta agonists
IL197025A0 (en) Aerosol formulation for the inhalation of beta agonists
IL197024A0 (en) Aerosol formulation for the inhalation of beta agonists
ZA200804654B (en) Powder compositions for inhalation
IL174496A0 (en) Aerosol formulation for inhalation, containing an anticholinergic agent
EP1993646A4 (en) CONFIGURATION OF NOZZLE PORES FOR INTRA-PULMONARY ADMINISTRATION OF AEROSOL FORMULATIONS
PL1727434T3 (pl) Dostarczanie funkcjonalnych składników
IL198854A0 (en) Powder formulation for valganciclovir
GB0416328D0 (en) Use of dry powder compositions for pulmonary delivery
ZA200807486B (en) Medicament formulations comprising fluoroquinolones
IL183930A0 (en) Use of cladribine for preparation of pharmaceutical compositions
ZA200806929B (en) Nebulizer formulation
SG152265A1 (en) Aerosol formulation for inhalation of beta agonists
EP1806148A4 (en) THERAPEUTIC PREPARATION FOR INHALATION
DK1809236T3 (da) Pulverformuleringer til inhalation indeholdende enatiomeriske rene beta-agonister
PT1496876E (pt) Formulação de aerossol para a inalação contendo brometo de tiotrópio
ZA200900370B (en) Aerosol formulation for the inhalation of beta agonists
ATE401861T1 (de) Tiotropiumhaltige pulverformulierung für die inhalation
HUE036427T2 (hu) Antikolinerg hatóanyagot tartalmazó, stabil, por alakú készítmény
GB0501956D0 (en) Nebulizer formulation
PT2167042E (pt) Composições de aerossóis farmacêuticas compreendendo fluticasona
ZA200900418B (en) Aerosol formulation for the inhalation of beta agonists
GB2451360B (en) Hormone replacement formulation
AP2006003734A0 (en) Inhalation formulation
ZA200606181B (en) Aerosol formulation